As multiple signaling pathways converge on RhoA to regulate OL biology, as well as the fact that RhoA-ROCK pathway inhibitors are currently in use for other CNS ailments [80], their efficacy in promoting remyelination in MS disease models remains an appealing direction for future investigation. This evidence concerns the gene RHOA and myeloid sarcoma.